Clinical applications of BCR-ABL molecular testing in acute leukemia

Journal of Molecular Diagnostics

Volumn 5, Issue 2, 2003, Pages 63-72

  Nashed, Amgad L ^a   Rao, Kathleen W ^a   Gulley, Margaret L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA; IMATINIB; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIOASSAY; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RECURRENCE; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC DISORDER; GENETIC TRANSCRIPTION; HEALTH CARE SYSTEM; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; OUTCOMES RESEARCH; PATIENT CARE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SOUTHERN BLOTTING;

EID: 0038365374     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60454-0     Document Type: Review

References (85)

1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497
2. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293
3. Davis RL, Konopka JB, Witte ON: Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 1985, 5:204-213
4. Pelz AF, Kröning H, Franke A, Wieacker P, Stumm M: High reliability and sensitivity of the bcr/ABL1 D-FISH test for the detection of BCR/ ABL rearrangements. Ann Hematol 2002, 81:147-153
5. Chase A, Grand F, Zhang J-G, Blackett N, Goldman M: Factors influencing false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 1997, 18: 246-253
6. Dewald GW, Schad CR, Christensen ER, Tiede AL, Zinsmeister AR, Spurbeck JL, Thibodeau SN, Jalal SM: The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogenet 1993, 71:7-14
7. Garcia-Isidoro M, Tabernero MD, Garcia JL, Najera ML, Hernandez JM, Wiegant J, Raap A, San Miguel J, Orfao A: Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection. Hum Pathol 1997, 28:154-159
8. Werner M, Ewig M, Nasarek A, Wilkens L, von Wasielewski R, Tchinda J, Nolte M: Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens. Diagn Mol Pathol 1997, 6:282-287
9. Wang YL, Bagg A, Pear W, Nowell PC, Hess JL: Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer 2001, 32:97-111
10. Lee DS, Kim EC, Yoon BH, Kim WH, Yoon JH, Cho HI: Can minor bcr/abl translocation in acute leukemia be discriminated from major bcr/abl by extra-signal FISH analysis? Haematologica 2001, 86:991-992
11. Grand FH, Chase A, Iqbal S, Nguyen DX, Lewis JL, Marley SB, Davidson RJ, Goldman JM, Gordon MY: A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia. Genes Chromosomes Cancer 1998, 23:109-115
12. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, Spurbeck JL, Silver RT: Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998, 91: 3357-3365
13. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW: A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998, 92:2315-2321
14. Gleissner B, Rieder H, Thiel E, Fonatsch C, Janssen LA, Heinze B, Janssen JW, Schoch C, Goekbuget N, Maurer J, Hoelzer D, Bartram CR: Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia 2001, 15:1834-1840
15. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86:3118-3122
16. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367
17. Yeoh E, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C, Evans WE, Naeve C, Wong L, Downing JR: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143
18. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU: Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987, 70:1584-1588
19. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547-561
20. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD: Clinical significance of the bcr-abl fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study. Blood 1992, 80:2983-2990
21. Mitterbauer G, Nemeth P, Wacha S, Cross NC, Schwarzinger I, Jaeger U, Geissler K, Greinix HT, Kalhs P, Lechner K, Mannhalter C: Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 1999, 106:634-643
22. Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, Ramond S, Viguie F, Marie JP, Zittoun R: Adult biphenotypic acute leukemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol 1998, 100:147-155
23. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99:1536-1543
24. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J: Philadelphia chromosome-positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome: a Pediatric Oncology Group study. Blood 1990, 76:489-494
25. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA: Clinical significance of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia in context of contemporary intensive therapies: a report from the children's cancer group. Cancer 1998, 83:2030-2039
26. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J: Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996, 10:957-963
27. Mori T, Manabe A, Tsuchida M, Hanada R, Yabe H, Ohara A, Saito T, Nakazawa S: Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) studies L89-12 and L92-13. Med Pediatr Oncol 2001, 37:426-431
28. Carbonell F, Swansbury J, Min T, Matutes E, Farahat N, Buccheri V, Morilla R, Secker-Walker L, Catovsky D: Cytogenetic findings in acute biphenotypic leukemia. Leukemia 1996, 10:1283-1287
29. Atlas of Genetics and Cytogenetics in Oncology and Haemotology. http://www.infobiogen.fr/services/chromcancer/Anomalies/ t0922ANL.html, Feb 16, 2003
30. Schrappe M, Aricò M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730-2741
31. Lim LC, Heng KK, Vellupillai M, Tan LT, Boey BC, Lau LC, How GF: Molecular and phenotypic spectrum of de novo Philadelphia positive acute leukemia. Int J Mol Med 1999, 4:665-667
32. Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR: Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 1994, 8:2118-2126
33. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC: p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996, 87:5213-5217
34. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R: Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991, 78:2411-2418
35. Secker-Walker LM, Craig JM: Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: a review. Leukemia 1993, 7:147-151
36. Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Kirk J, Lee A, Kessler P, Appelbaum F, Gehly G: Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994, 8:1688-1695
37. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR: Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, 89: 2602-2609
38. Dombret H, Gabert J, Boiron J-M, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Babera C, Cayuela J-M, Fenaux P, Bourhis J-H, Fegeuex N, Charrin C, Boucheix C, Lheritier V, Esperou H, MacInyre E. Vernant J-P, Fiere D: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002; 2357-2366
39. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88:2375-2384
40. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, de Micheli D, Parziale A, Fornaci MN, Martinelli G, Salvatore F: Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996, 87:1075-1080
41. Saglio G, Pane F, Martinelli G, Guerrasio A: BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle. Leuk Lymphoma 1997, 26:281-286
42. Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R: Appearance of acute leukemia-associated P190 BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. Leukemia 1991, 5:191-195
43. Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo JA, Herrera C, Gonzalez MG, Reina L, Rodriguez MC, Alvarez MA, Maldonado J, Torres A: Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 (BCR-ABL) and pl90(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 (BCR-ABL) detection precedes cytogenetic relapse. Blood 2000, 95:2659-2665
44. Onciu M, Bueso-Ramos C, Medeiros J, Ball G, Smith T, Lai R: Acute lymphoblastic leukemia in elderly patients: the Philadelphia chromosome may not be a significant adverse prognostic factor. Am J Clin Pathol 2002, 117:716-720
45. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven J, Zomas A, Atra A, Catovsky D: Outcome of biphenotypic acute leukemia. Haematologica 1999, 84:699-706
46. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991, 77:435-439
47. Friedmann AM, Weinstein HJ: The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist 2000, 5:321-328
48. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, Lepage E, Thomas X, Fiere D: Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000, 14:1353-1366
49. Mandelli F, Annino L, Rotoli B: The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br J Haematol 1996, 92:665-672
50. Forman SJ, O'Donnell MR, Nademanee AP, Snyder DS, Bierman PJ, Schmidt GM, Fahey JL, Stein AS, Parker PM, Blume KG: Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987, 70:587-588
51. Snyder DS, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Margolin K, Somlo G, Molina A, Spielberger R, Kashyap A, Fung H, Slovak ML, Dags A, Negrin RS, Amylon MD, Blume KG, Forman SJ: Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999, 13: 2053-2058
52. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99:3547-3553
53. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539
54. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880
55. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP: Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99:1860-1862
56. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475
57. Verma A, Stock W: Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 2001, 13:14-20
58. Sievers EL, Radich JP: Detection of minimal residual disease in acute leukemia. Curr Opin Hematol 2000, 7:212-216
59. Faderl S, Kantarjian HM, Talpaz M, Estrov Z: Clinical significance of minimal residual disease in leukemia. Int J Oncol 2000, 17:1277-1287
60. Cimino G, Elia L, Rapanotti MC, Sprovieri T, Mancini M, Cuneo A, Mecucci C, Fioritoni G, Carotenuto M, Morra E, Liso V, Annino L, Saglio G, De Rossi G, Foa R, Mandelli F: A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000, 95:96-101
61. Pallisgaard N, Clausen N, Schroder H, Hokland P: Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999, 26:355-365
62. Saffroy R, Lemoine A, Brezillon P, Frenoy N, Delmas B, Goldschmidt E, Souleau B, Nedellec G, Debuire B: Real-time quantitation of bcr-abl transcripts in haematological malignancies. Eur J Haematol 2000, 65:258-266
63. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real-time quantitative RT-PCR. Leukemia 1999, 13:1825-1832
64. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T: Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002, 16:53-59
65. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B: Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999, 13:1383-1389
66. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA: LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999, 59:3171-3174
67. Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G: Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica 2001, 86:252-259
68. Bolufer P, Sanz GF, Barragan E, Sanz MA, Cervera J, Lerma E, Senent L, Moreno I, Planelles MD: Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes. Haematologica 2000, 85:1248-1254
69. Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U: Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000, 46:913-920
70. Kreuzer KA, Lass U, Nagel S, Ellerbrok H, Pauli G, Pawlaczyk-Peter B, Siegert W, Huhn D, Schmidt CA: Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients. Int J Cancer 2000, 86:741-746
71. Stockschlader M, Hegewisch-Becker S, Kruger W, tom Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschutter B, Martin H, Peters S, Kalisch H, Kuse R, Weh H, Zander A: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995, 16:663-667
72. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, Edmands S, Flowers ME, Kerkof K, Nelson R, Appelbaum FR: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001, 98:1701-1707
73. Gehly GB, Bryant EM, Lee AM, Kidd PG, Thomas ED: Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1991, 78:458-465
74. Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M, Kodera Y, Kojima S, Matsuyama K, Hirabayashi N: Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992, 79: 1366-70
75. Lin F, Goldman JM, Cross NC: A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994, 86:683-685
76. Bock O, Lehmann U, Kreipe H: Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myelogenous leukemia. J Mol Diagn 2003, 5:54-60
77. Matsue K, Tabayashi T, Yamada K, Takeuchi M: Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2002, 29:63-66
78. Porter DL, Collins RH Jr., Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH: Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999, 5:253-261
79. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, vanRhee F, Kaeda J, Cross NCP, Craddock C, Kanfer E, Apperley J, Goldman JM: Molecular studies in patients with chronic myeloid leukemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574
80. Bagg A: Chronic Myeloid Leukemia: a minimalist view of post-therapeutic monitoring. J Mol Diagn 2002, 4:1-10
81. Lion T: Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia: the European Investigators on Chronic Myeloid Leukemia Group. Bone Marrow Transplant 1994, 14:505-509
82. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000, 95:62-66
83. Lin F, vanRhee F, Goldman JM, Cross NC: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478
84. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NCP, Goldman JM: Early Detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565
85. National Comprehensive Cancer Network Practice Guidelines for Chronic Myelogenous Leukemia. Version 1.2002;10/30/01